SIGACHI37.60

Sigachi Industries Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersLINCOLNTHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYNGLFINEMcap ₹1,437 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations99.2110.9104.195.7124.9139.4128.2128.2110.5117.2121.9121.3
Other Income1.11.77.21.714.62.02.23.92.50.51.31.0
Total Income100.3112.7111.497.4139.5141.4130.4132.2113.0117.7123.2122.3
Expenses
+ Cost of Materials Consumed39.436.547.541.864.459.669.661.642.553.941.754.7
+ Purchases of Stock-in-Trade1.519.317.20.5-0.24.4-1.62.710.45.410.96.0
+ Changes in Inventories5.00.0-11.3-2.01.90.8-17.0-1.67.46.06.8-3.0
+ Employee Benefit Expense14.714.015.615.118.419.520.619.621.823.728.828.4
+ Finance Costs1.81.82.93.22.13.83.33.33.13.14.33.0
+ Depreciation & Amortisation2.52.83.53.13.24.74.74.74.14.24.64.4
+ Other Expenses17.218.618.719.223.222.028.121.820.822.617.318.7
Total Expenses82.193.094.281.0113.0114.7107.7112.2110.2118.8114.4112.2
EBITDA21.422.616.321.017.233.228.624.17.55.716.416.5
EBIT18.919.812.817.914.028.523.819.43.41.511.812.1
Profit
PBT before Exceptional Items18.219.617.216.426.526.722.720.02.8-1.18.810.1
+ Exceptional Items0.00.00.00.00.00.00.0-121.04.7-0.7-1.10.0
Pretax Income18.219.617.216.426.526.722.7-101.07.4-1.97.710.1
+ Current Tax1.73.03.93.13.63.84.10.10.50.41.42.6
+ Deferred Tax1.40.5-1.80.51.92.42.4-0.1-3.6-2.3-1.3-0.6
Tax Expense3.13.52.03.65.56.26.5-0.0-3.1-1.80.11.9
Net Income15.116.115.212.821.020.516.2-101.010.5-0.07.68.1
+ Net Income — Continuing Ops15.116.115.212.821.020.516.2-101.010.5-0.07.68.1
+ Other Comprehensive Income-0.1-0.10.20.00.10.1-0.4-0.0-0.21.61.81.9
Total Comprehensive Income15.016.015.412.821.220.615.8-101.010.31.69.410.0
Net Income to Common15.116.115.021.821.413.3-100.410.70.27.76.8
Minority Interest-0.0-0.00.1-0.8-0.82.9-0.6-0.2-0.2-0.11.4
Per Share
Basic EPS4.930.510.480.400.660.650.36-2.630.280.010.200.18
Diluted EPS4.480.430.410.320.530.520.39-2.630.280.010.200.18
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.4-0.0-0.21.61.81.9
+ Items NOT to be Reclassified to P&L-0.0-0.00.10.00.10.1-1.00.1-0.00.1-0.20.1
+ Tax on Items NOT to be Reclassified-0.20.00.00.0-0.10.0
+ Tax on Items NOT to be Reclassified — alt tag-0.00.00.00.00.00.0
+ Items to be Reclassified to P&L-0.0-0.00.10.00.00.00.4-0.1-0.21.61.91.8
Comprehensive Income — Owners of Parent15.116.015.213.221.921.413.0-100.3-0.21.89.48.7
Comprehensive Income — Non-controlling Interests-0.0-0.00.1-0.4-0.8-0.82.8-0.6-0.0-0.2-0.01.4
Per Share — as-filed variants
Basic EPS — Continuing Operations4.930.510.480.400.660.650.36-2.630.280.010.200.18
Diluted EPS — Continuing Operations4.480.430.410.320.530.520.39-2.630.280.010.200.18
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit53.455.250.655.458.874.777.265.450.252.062.563.6
Gross Margin %53.8049.7448.6357.8547.1053.5660.2551.0345.4144.3451.2952.47
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)18.219.617.216.426.526.722.720.02.8-1.18.810.1
− Exceptional Items (reconciliation)0.00.00.00.00.00.00.0-121.04.7-0.7-1.10.0
Net Income Adj (tax-effected)15.116.115.212.821.020.516.220.05.90.38.88.1
EPS Adj4.930.510.480.400.660.650.360.520.16-0.170.230.18
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.001.001.001.001.001.001.001.001.001.001.001.00
Paid Up Equity Capital30.732.332.832.833.333.338.238.238.238.238.238.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.